AbbVie Rinvoq Growth Decelerates to 20.2%, Q2 Earnings Call Set for July 31
ABBV•AbbVie's Rinvoq sales growth slowed to 20.2% year-over-year in the latest quarter, down from 28.6% in the prior period, signaling increased competition risk. The company will announce second-quarter 2026 results on July 31 before markets open and host an 8 a.m. CT earnings call to review performance.
1. Rinvoq Growth Slows to 20.2% Year-Over-Year
AbbVie reported that Rinvoq global sales grew 20.2% year-over-year in the latest quarter, down from 28.6% operational growth in the prior period. This deceleration raises concerns about intensifying competition in immunology and heightens reliance on Skyrizi’s accelerating 29.2% growth to sustain top-line momentum.
2. Q2 Earnings Call Scheduled for July 31
The company will release second-quarter 2026 financial results on July 31 before markets open, followed by an 8 a.m. CT conference call. Investors can expect management commentary on product performance, competitive pressures, and full-year guidance during the live webcast.
